• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Prelude Therapeutics Inc (NQ: PRLD )

    1.235 -0.005 (-0.40%)
    Streaming Delayed Price Updated: 12:10 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 118,853
    Open 1.250
    Bid (Size) 1.230 (2)
    Ask (Size) 1.240 (3)
    Prev. Close 1.240
    Today's Range 1.210 - 1.288
    52wk Range 1.100 - 6.800
    Shares Outstanding 54,808,715
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
    PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) 
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire

    Performance

    YTD
    -69.66%
    -69.66%
    1 Month
    -38.25%
    -38.25%
    3 Month
    -75.88%
    -75.88%
    6 Month
    -67.75%
    -67.75%
    1 Year
    -58.14%
    -58.14%

    More News

    Read More
    Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know
    Via Benzinga
    Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024
    Via InvestorPlace
    Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
    Via Talk Markets
    Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    AI Meets Biotech: 3 Top Stocks Transforming Medical Science
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Prelude Therapeutics Announces $25 Million Private Placement
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
    From AbCellera Biologics Inc.
    Via Business Wire
    Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
    From Prelude Therapeutics, Inc.; AbCellera
    Via GlobeNewswire
    Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.